Read the full story by clicking on this headline.. |
Amylyx Pharmaceuticals Inc on Friday set the list price of its newly approved drug to treat amyotrophic lateral sclerosis (ALS) at about $158,000 per year in the United States, a discount to its most recently approved competitor. The drug Relyvrio was approved by the U.S.... |
0 Comments
Leave a Reply. |
NewsMaxA conservative American news and opinion website founded by Christopher Ruddy in 1998 & operated by Newsmax Media. Archives
June 2023
Categories |